000			01247na a2200181 4500
999			_c1660 _d1660
003			PC1660
005			20210625062756.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91010 _aPablos Álvarez, José Luis _eReumatología
245	0	0	_aBiologic therapy in rheumatoid arthritis. _h[artículo]
260			_bCurrent Topics in Medicinal Chemistry, _c2013
300			_a13(6):752-9.
500			_aFormato Vancouver: Cañete JD, Pablos JL. Biologic therapy in rheumatoid arthritis. Curr Top Med Chem. 2013;13(6):752-9.
501			_aPMID: 23574524
504			_aContiene 87 referencias
520			_aBiologic therapies have notably improved the treatment of RA, making disease remission a realistic goal. After more than ten years of experience, the safety issues associated with these drugs are well characterized and can be avoided with careful patient selection and tight clinical control. Although the different biologic drugs (anti-TNF agents, anti-IL-6, anti-B cells and anti-costimulation of T-cells) have apparently different mechanisms of action, all biologic agents have demonstrated similar efficacy. In addition results of the combination of two biologic therapies have shown no additive clinical effects, although there is an increased risk of infection. Therefore, further research is needed to optimize the use of these and future targeted therapies in RA.
710			_9123 _aServicio de Reumatología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1660.pdf _ySolicitar documento
942			_n0 _2ddc _cART